Lantheus Holdings (LNTH) Income towards Parent Company (2014 - 2026)
Lantheus Holdings (LNTH) reported Income towards Parent Company of $118.4 million for Q1 2026, up 62.34% year-over-year from $72.9 million in Q1 2025, and up 118.93% quarter-over-quarter from $54.1 million in Q4 2025.
Lantheus Holdings (LNTH) Income towards Parent Company (2014 - 2026) Analysis & Trends
Lantheus Holdings (LNTH) has 13 years of Income towards Parent Company data on file, last reported at $118.4 million in Q1 2026.
- Income towards Parent Company for Q1 2026 came in at $118.4 million, up 62.34% year-over-year; the trailing twelve-month figure through Mar 2026 was $279.0 million (up 25.01% YoY), and the FY2025 annual result was $233.6 million, down 16.98% from the prior year.
- Income towards Parent Company grew to $118.4 million in Q1 2026 per LNTH's latest filing, from $54.1 million in the prior quarter.
- Over five years, Income towards Parent Company peaked at $132.0 million in Q3 2023 and troughed at -$119.2 million in Q4 2022.
- A 5-year average of $58.1 million and a median of $62.1 million in 2024 frame the typical range for Income towards Parent Company.
- The sharpest annual moves came in 2022 and 2024: Income towards Parent Company plunged 196.37% in 2022, then jumped 4769.26% in 2024.
- A 5-year view of Income towards Parent Company shows it stood at -$119.2 million in 2022, then surged by 186.74% to $103.4 million in 2023, then tumbled by 141.49% to -$42.9 million in 2024, then surged by 226.09% to $54.1 million in 2025, then soared by 118.93% to $118.4 million in 2026.
- Business Quant data shows LNTH's Income towards Parent Company at $118.4 million in Q1 2026, $54.1 million in Q4 2025, and $27.8 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 38.77 Bn | 35.04 Bn | 1.97 Bn |
| 2 | Zoetis | 34.11 Bn | 32.16 Bn | 1.62 Bn |
| 3 | United Therapeutics | 23.68 Bn | 21.53 Bn | 648.10 Mn |
| 4 | Aurora Cannabis | 16.48 Bn | 16.40 Bn | 33.43 Mn |
| 5 | Neurocrine Biosciences | 16.19 Bn | 14.88 Bn | 800.70 Mn |
| 6 | Elanco Animal Health | 11.44 Bn | 11.01 Bn | 785.00 Mn |
| 7 | Alkermes | 7.28 Bn | 6.77 Bn | -116.06 Mn |
| 8 | Lantheus Holdings | 6.48 Bn | 5.98 Bn | 230.92 Mn |
| 9 | Hims & Hers Health | 6.35 Bn | 5.60 Bn | 396.79 Mn |
| 10 | Liquidia | 5.74 Bn | 5.52 Bn | 121.79 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 118.42 Mn |
| Dec 31, 2025 | 54.09 Mn |
| Sep 30, 2025 | 27.77 Mn |
| Jun 30, 2025 | 78.76 Mn |
| Mar 31, 2025 | 72.95 Mn |
| Dec 31, 2024 | -42.90 Mn |
| Sep 30, 2024 | 131.09 Mn |
| Jun 30, 2024 | 62.07 Mn |
| Mar 31, 2024 | 131.07 Mn |
| Dec 31, 2023 | 103.38 Mn |
| Sep 30, 2023 | 131.96 Mn |
| Jun 30, 2023 | 94.13 Mn |
| Mar 31, 2023 | -2.81 Mn |
| Dec 31, 2022 | -119.19 Mn |
| Sep 30, 2022 | 61.23 Mn |
| Jun 30, 2022 | 43.06 Mn |
| Mar 31, 2022 | 42.96 Mn |
| Dec 31, 2021 | -40.22 Mn |
| Sep 30, 2021 | -13.42 Mn |
| Jun 30, 2021 | -26.66 Mn |